WebMD

Thymidine Kinase 2 Deficiency (TK2d)

What Is Thymidine Kinase 2 Deficiency (TK2d)? Thymidine kinase 2 deficiency (TK2d) mainly causes muscle weakness. It’s a very rare mitochondrial disease. Mitochondria are tiny organ-like structures ...
Yahoo Finance

Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d)

First published data from a multicenter retrospective chart review study to explore the safety and efficacy of pyrimidine nucleoside and/or nucleotide therapy in patients with thymidine kinase 2 ...
pharmaphorum

UCB brings first therapy for rare disease TK2d to EU

Patients in the EU with rare disease thymidine kinase 2 deficiency (TK2d) have their first approved therapy, UCB's Kygevvi, after the European Commission cleared the drug "under exceptional ...
WebMD

What Should I Know About Kygevvi for Treatment of Thymidine Kinase 2 Deficiency?

Thymidine kinase 2 deficiency (TK2d) is a very rare genetic disease that causes muscle weakness, which can happen in different parts of your body. TK2d can sometimes be severe and affect your ability ...
pharmaphorum

UCB drug for rare disease TK2d boosts survival

UCB's experimental medicine for rare disease thymidine kinase 2 deficiency (TK2d) has been shown to reduce the risk of death by a massive 95% in a study, as marketing applications are reviewed in the ...
PharmiWeb

U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)

“The approval of doxecitine and doxribtimine represents a pivotal moment for the TK2d community who previously had no FDA-approved treatment options for this rare genetic mitochondrial disease beyond ...
MedCity News

UCB Drug Becomes First FDA-Approved Treatment for Ultra-Rare and Fatal Mitochondrial Disease

The energy that powers cells of the human body comes from tiny cellular components called mitochondria. Just as a draining battery makes it difficult to operate an electronic device, mitochondrial ...
The Pharma Letter

Over 90% reduced death risk with treatment in subgroup for ultra rare TK2d disease

New data published in Brain Communications offers a strong picture of how devastating thymidine kinase 2 deficiency (TK2d) ...
Pharmabiz

UCB publishes data on Brain Communications demonstrating positive impact of Kygevvi

UCB, a global biopharmaceutical company, announced the publication of two manuscripts in Brain Communications. One manuscript reports integrated safety and efficacy findings for Kygevvi (doxecitine ...

UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI® (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 ...

UCB, a global biopharmaceutical company, today announced the publication of two manuscripts in Brain Communications. One manuscript reports integrated safety and efficacy findings for KYGEVVI® ...
manilatimes

FDA Approves KYGEVVI® (doxecitine and doxribtimine), the First and Only Treatment for Adults and Children Living with Thymidine Kinase 2 deficiency (TK2d), a Rare and ...

New York, Nov. 03, 2025 (GLOBE NEWSWIRE) -- New York, Monday, November 3, 2025 - The Muscular Dystrophy Association (MDA) marks another milestone today in our legacy of progress with the FDA approval ...